These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12394255)

  • 1. Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study.
    Salminen E; Korpela J; Varpula M; Asola R; Varjo P; Pyrhönen S; Mali P; Hinkka S; Ekholm E
    Anticancer Drugs; 2002 Oct; 13(9):925-9. PubMed ID: 12394255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
    Viens P; Roché H; Kerbrat P; Fumoleau P; Guastalla JP; Delozier T
    Am J Clin Oncol; 2001 Aug; 24(4):328-35. PubMed ID: 11474255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer.
    Milla-Santos A; Milla L; Rallo L; Solano V
    Am J Clin Oncol; 2001 Apr; 24(2):138-42. PubMed ID: 11319287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
    Pagani O; Sessa C; Nolè F; Crivellari D; Lombardi D; Thürlimann B; Hess D; Borner M; Bauer J; Martinelli G; Graffeo R; Zucchetti M; D'Incalci M; Goldhirsch A
    Ann Oncol; 2000 Aug; 11(8):985-91. PubMed ID: 11038035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG).
    Kouroussis C; Xydakis E; Potamianou A; Giannakakis T; Kakolyris S; Agelaki S; Sara E; Malamos N; Alexopoulos A; Mavroudis D; Samonis G; Papadouris S; Georgoulias V; Panagos G
    Ann Oncol; 1999 May; 10(5):547-52. PubMed ID: 10416004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
    Yeo W; Mok TS; Tse KK; Kwan WH; Lam KC; Ho WM; Chiu SK; Chan AT; Leung TW; Mo FK; Johnson PJ
    Anticancer Drugs; 2002 Jul; 13(6):655-62. PubMed ID: 12172512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel and epirubicin in advanced breast cancer.
    Sessa C; Pagani O
    Oncologist; 2001; 6 Suppl 3():13-6. PubMed ID: 11346679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.
    Venturini M; Michelotti A; Papaldo P; Del Mastro L; Bergaglio M; Lionetto R; Lunardi G; Sguotti C; Frevola L; Donati S; Rosso R; Cognetti F
    Ann Oncol; 2001 Aug; 12(8):1097-106. PubMed ID: 11583191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
    Venturini M; Del Mastro L; Garrone O; Angiolini C; Merlano M; Bergaglio M; Tolino G; Lambiase A; Baldini A; Canavese G; Rosso R
    Ann Oncol; 2002 Apr; 13(4):546-52. PubMed ID: 12056704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer.
    Airoldi M; Cattel L; Pedani F; Marchionatti S; Tagini V; Bumma C; Recalenda V
    Breast Cancer Res Treat; 2001 Dec; 70(3):185-95. PubMed ID: 11804182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
    Polyzos A; Tsavaris N; Kosmas C; Gogas H; Vadiaka M; Markopoulos C; Giannopoulos A; Kalahanis N; Stamatiadis D; Kouraklis G; Karatzas G; Liapis C; Syrigos K
    Anticancer Res; 2003; 23(3C):2917-23. PubMed ID: 12926135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
    Spielmann M; Tubiana-Hulin M; Namer M; Mansouri H; Bougnoux Ph; Tubiana-Mathieu N; Lotz V; Eymard JC
    Br J Cancer; 2002 Mar; 86(5):692-7. PubMed ID: 11875727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor.
    Kwasny W; Kornek G; Haider K; Valencak J; Ulrich-Pur H; Penz M; Lang F; Depisch D; Scheithauer W
    Breast Cancer Res Treat; 2000 Oct; 63(3):235-41. PubMed ID: 11110057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients.
    Hénin E; Meille C; Barbolosi D; You B; Guitton J; Iliadis A; Freyer G
    Breast Cancer Res Treat; 2016 Apr; 156(2):331-41. PubMed ID: 27002506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
    Im SA; Kim SB; Lee MH; Im YH; Lee KH; Song HS; Lee MA; Lee J; Lee NS; Ham HS; Kim TY; Park YH; Lee KE; Kim KW; Seo JH; Lee SN; Hong YS; Bang YJ; Kim WK; Park HS
    Oncol Rep; 2005 Aug; 14(2):481-7. PubMed ID: 16012734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study.
    Mavroudis D; Alexopoulos A; Ziras N; Malamos N; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Tsavaris N; Potamianou A; Rigatos G; Georgoulias V
    Ann Oncol; 2000 Oct; 11(10):1249-54. PubMed ID: 11106112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
    Pagani O
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):23-6. PubMed ID: 9865708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
    Venturini M; Durando A; Garrone O; Colozza MA; Contu A; Stevani I; Genta F; Bighin C; Lambiase A; Del Mastro L
    Cancer; 2003 Mar; 97(5):1174-80. PubMed ID: 12599222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer.
    Khayat D; Chollet P; Antoine EC; Monfardini S; Ambrosini G; Benhammouda A; Mazen MF; Sorio R; Borg-Olivier O; Riva A; Ramazeilles C; Azli N
    J Clin Oncol; 2001 Jul; 19(14):3367-75. PubMed ID: 11454884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study.
    Humphreys AC; Dent J; Rodwell S; Crawford SM; Joffe JK; Bradley C; Dodwell D; Perren TJ
    Br J Cancer; 2004 Jun; 90(11):2131-4. PubMed ID: 15150554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.